CMPX NASDAQ
Compass Therapeutics, Inc.
1W: -2.5%
1M: -63.7%
3M: -68.7%
YTD: -62.7%
1Y: -8.1%
3Y: -41.0%
5Y: -54.6%
$2.07
+0.14 (+7.25%)
Weekly Expected Move ±33.8%
$1
$1
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (40)
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics to Participate in Upcoming May Investor Events
Compass Therapeutics GAAP EPS of -$0.10 in-line
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
William Blair updates conviction stock list
Compass Therapeutics plunges on tovecimig missing overall survival endpoint
12 Health Care Stocks Moving In Monday's Intraday Session
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
US Stocks Mixed; Nasdaq Falls Over 100 Points
12 Health Care Stocks Moving In Monday's Pre-Market Session
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Biggest stock movers Monday: OGN, QCOM, and more
12 Health Care Stocks Moving In Friday's After-Market Session
Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year
Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Compass Therapeutics (NASDAQ:CMPX) Shares Down 5.4% – Here’s What Happened
Compass Therapeutics Sees Unusually High Options Volume (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings
Analysts Issue Forecasts for CMPX Q1 Earnings
Compass Therapeutics GAAP EPS of -$0.09
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next?
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade